REFRACTORY MIGRAINE: MODERN METHODS OF MEDICAL THERAPY

Abstract


There were described modern methods of medical therapy of refractory migraine, being a clinical variation of the migraine, in which there is absence or minimal effect of the standard therapy with the proved efficacy both for attacks prevention and for coping them. Due to this therapeutic tactics of this category of patients is rather difficult for neurologists. Multidisciplinary approach is the basis of long-term and stable clinical improvement, when rational combined pharmacotherapy is coupled with a big range of nonmedicinal drugs.

About the authors

Evgenia V Ekusheva

The first I.M. Sechenov Moscow state medical university

Email: ekushevaev@mail.ru
119991, Моscow, Trubetskaya street, 8, building 2
laboratory of vegetative system pathology

Igor V Damulin

The first I.M. Sechenov Moscow state medical university

Email: damulin@mmascience.ru
119991, Моscow, Trubetskaya street, 8, building 2
department of nervous diseases and neurosurgery

References

  1. Азимова Ю.Э., Маргулис М.И., Табеева Г.Р. Рефрактерная мигрень: от патогенеза к рациональной терапии // Русский медицинский журнал. 2011. № 1. С. 18-19.
  2. Екушева Е.В. Оптимальные подходы к купированию приступа мигрени: прошлое, настоящее и будущее // Русский медицинский журнал. 2012. № 10. С. 522-528.
  3. Екушева Е.В., Филатова Е.Г. Залдиар в лечении приступов мигрени // Журнал невролог. и психиатр. им. С.С. Корсакова. 2007. № 107. С. 74-76.
  4. Филатова Е.Г., Вейн А.М. Мигрень // Consilium medicum. 1999. № 1(2). С. 60-65.
  5. Яхно H.H., Орлова O.P., Артеменко А.Р. и др. Лечение головных болей препаратом лантокс. Медицинская технология. Разрешение на применение новой медицинской технологии. ФС №2008/288. Москва, 2008. 28 с.
  6. Ashina S., Serrano D., Lipton R.B. et al. Depression and risk of transformation of episodic to chronic migraine // J. Headache Pain. 2012. Vol. 13. P. 615-624.
  7. Ashkenazi A., Silberstein S. Botulinum toxin type A for the treatment of headache: why we say yes // Arch. Neurol. 2008. Vol. 65(1). P. 146-149.
  8. Ashkenazi A., Benlifer A., Korenblit J. et al. Zonizamide for migraine prophpylaxis inrefractory patients // Cephalalgia. 2006. Vol. 26. P. 1199-1202.
  9. Aurora S.K., Silberstein S.D., Kori S.H. et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine // Headache. 2011. Vol. 51. P. 507-517.
  10. Aurora S.K., Dodick D.W., Turkel C.C. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial // Cephalalgia. 2010. Vol. 30(7). P. 793-803.
  11. Bermejo P.E., Dorado R. Zonizamide for migraine prophylaxis in patients refractory to topiramate // Clin. Neuropharmacol. 2009. Vol. 32. P. 103-106.
  12. Bigal M.E., Rapoport A., Sheftell F. et al. Memantine in the preventive treatment of refractory migraine // Headache. 2008. Vol. 48. P. 1337-1342.
  13. Blumenfeld A., Silberstein S.D., Dodick D.W. et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program // Headache. 2010. Vol. 50(9). P. 1406-1418.
  14. Cady R.K., Schreiber C.P., Porter J.A. et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine // Headache. 2011. Vol. 51. P. 21-32.
  15. Diener H.C., Dodick D.W., Aurora S.K. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial // Cephalalgia. 2010. Vol. 30 (7). P. 804-814.
  16. Dodick D.W., Turkel C.C., DeGryse R. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program // Headache. 2010. Vol. 50. P. 921-936.
  17. Dodick D.W. Reflections and speculations on refractory migraine: why do some patients fail to improve with currently available therapies // Headache. 2008. Vol. 46(6). P. 828-837.
  18. Dodick D.W. Triptan nonresponder studies: implications for clinical practice // Headache. 2005. Vol. 45. P. 156-162.
  19. Dodick D.W., Mauskop A., Elkind A.H. et al. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study // Headache. 2005. Vol. 45(4). P. 315-324.
  20. Evans R.W. A rational approach to the management of chronic migraine // Headache. 2013. Vol. 53. P. 168-176.
  21. Gerwin R.R. Treatment of chronic migraine headache with onabotulinumtoxinA // Curr. Pain Headache Rep. 2011. Vol. 15(5). P. 336-338.
  22. Goadsby P.J., Schoenen J., Ferrari M.D. et al. Towards a definition of interactable headache for use in clinical practice and trials // Cephalalgia. 2006. Vol. 26. P. 1168-1170.
  23. Ifergane G., Wirguin I., Shvartzman P. Triptans - Why once? // Headache: The Journal of Head and Face Pain. 2006. Vol. 46(8). P. 1261-1263.
  24. Irimia P., Palma J.A., Fernandez-Torron R., Martinez-Vila E. Refractory migraine in a headache clinic population // BMC Neurol. 2011. Vol. 11. P. 94-98.
  25. Katsarava Z., Schneeweiss Kurth T., Kroener U. et al. Incidence and predictors for chronicity of headache in patients with episodic migraine // Neurology. 2004. Vol. 62. P. 788-790.
  26. Krusz J.C. Belanger J., Cagle J. Treatment of refractory migraines: high success rate in the clinic. Poster Abstract. 49th Annual Scientific Meeting of the American Headache Society. Chicago // Headache. 2007. Vol. 47. P. 752.
  27. Krymchantowski A.V., Jevoux C.C. Low-dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy // Headache. 2012. Vol. 52(1). P. 129-132.
  28. Krymchantowski A.V., Jevoux C.С., Moreira P.F. An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine // Pain Med. 2010. Vol. 11(1). P. 48-52.
  29. Krymchantowski A, Jevoux C.С. Memantine in the preventive treatment for migraine and refractory migraine // Headache. 2009. Vol. 49. P. 481-482.
  30. Krymchantowski A.V., Barbosa J.S. Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug // Arq. Neuropsiquiatr. 2001. Vol. 59(3-В). P. 708-711.
  31. Levin M. Opioids in headache // Headache. 2013. Vol. 48(6). P. 783-790.
  32. Levin М., Schulman Е. Refractory migraine: definition and classification. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 19-34.
  33. Lipton R.B., Bigal M.E. Epidemiology of refractory migraine. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 35-45.
  34. Lipton R.B., Silberstein S.D. The role of headache-related disability in migraine management: implications for headache treatment guidelines // Neurology. 2001. Vol. 56 (6, suppl. 1). P. S35-S842.
  35. Lovell B.V., Marmura M.J. New therapeutic developments in chronic migraine // Curr. Opin. Neurol. 2010. Vol. 23. P. 254-258.
  36. Magalhaes E., Menezes C., Cardeal M. et al. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine // Clin. Neurol. Neurosurg. 2010. Vol. 112(6). P. 463-466.
  37. Maizels M. Clonazepam for refractory headache: three cases illustrative of benefit and risk // Headache. 2010. Vol. 50, P. 650-656.
  38. Matak I., Bach-Rojecky L., Filipovic B. et al. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A // Neuroscience. 2011. Vol. 186. P. 201-207.
  39. Mathew N.T. Prophylactic treatment of refractory migraine. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 101-116.
  40. Mathew N.T., Jaffri S.F. A double-blind comparison of onabotulinumtoxinА (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: a pilot study // Headache. 2009 Vol. 49. P. 1466-1478.
  41. McGeeney B.E. Acute and urgent treatment of refractory migraine. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 116-136.
  42. Nagy A.J., Gandhi S., Bhola R. et al. Intravenous dihydroergotamine for inpatient management of refractory primary headaches // Neurology. 2011. Vol. 77. P. 1827-1832.
  43. Oterino A., Ramon C., Pascual J. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks // J. Headache Pain. 2012. Vol. 12. P. 235-238.
  44. Palmisani S., Al-Kaisy A., Arcioni R. et al. A six year retrospective review of occipital nerve stimulation practice - controversies and challenges of an emerging technique for treating refractory headache syndromes // J. Headache Pain. 2013. Vol. 14 (1). P. 67-72.
  45. Pascual-Gomez J., Gracia-Naya M., Leira R. et al. Zonisamide in the preventive treatment of refractory migraine // Rev. Neurol. 2010. Vol. 50. P. 129-132.
  46. Rapoport A.M., Bigal M.E., Volcy M. et al. Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases // Headache. 2003. Vol. 43(5). P. 482-489.
  47. Robbins L. Refractory chronic migraine: longterm follow-up using a refractory rating scale // J. Headache Pain. 2012. Vol. 13. P. 225-229.
  48. Robbins L. Refractory chronic migraine // Рract. Pain Manag. 2010. Vol. 10. P. 10-24.
  49. Robbins L. Long-acting opioids for refractory chronic migraine // Pract. Pain Manag. 2009. Vol. 9(6). P. 74-78.
  50. Robertson C.E., Garza I. Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine // Neuropsych. Dis. Treatm. 2012. Vol. 8. P. 35-48.
  51. Rothrock J.F. Treatment refractory migraine: the case for opioid therapy // Headache. 2008. Vol. 48. P. 850-854.
  52. Saper J.R., Lake A.E. Inpatient Strategies for Refractory Migraine. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 314-341.
  53. Scher A.I., Stewart W.F., Ricci J.A. et al. Factors associated with the onset and remission of chronic daily headache in a population-based study // Pain. 2003. Vol. 106. P. 81-89.
  54. Schulman E.A., McGeeney B.E. Current concepts in refractory migraine // Curr. Treat. Opitions Neurol. 2013. Vol. 15(1). P. 40-55.
  55. Schulman Е. Historical overview of refractory headachе. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 5-18.
  56. Schulman E.A., Peterlin B.L., Lake A.E. et al. Defining refractory migraine: results of the RHSIS survey of American headache society members // Headache. 2009. Vol. 49. P. 509-518.
  57. Schulman E.A., Lake A.E., Goadsby P.J. et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American headache society // Headache. 2008. Vol. 48. P. 778-782.
  58. Schulman E.A., Traumuta G. Refractory headache // Headache. 1993. Vol. 33. P. 273-286.
  59. Sheftell F.D., Rapoport A.M., Tepper S.J. et al. Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study // Headache. 2005. Vol. 45(10). P. 1400-1406.
  60. Silberstein S.D., Dodick D.W., Saper J. et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study // Cephalalgia. 2012. Vol. 32. P. 1165-1179.
  61. Silberstein S.D., Dodick D.W., Pearlman S. Defining the pharmacologically interactable headache for clinical trials and clinical practice // Headache. 2010. Vol. 50. P. 1499-1506.
  62. Silberstein S.D., Stark S.R., Lucas S.M. et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial // Mayo Clin. Proc. 2005. Vol. 80(9). P. 1126-1137.
  63. Tepper S.J., Tepper D.E. Medication overuse headache in refractory migraine and its treatment. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 136-160.
  64. Tepper S.J., Bigal M.E., Sheftell F.D. et al. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases / Headache. 2004. Vol. 44(8). P. 794-800.
  65. Tobin J., Filtman S. Occipital nerve blocks: when and what to inject? // Headache. 2009. Vol. 49. P. 1521-1533.
  66. Togha M., Rahmat J.M. et al. Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate // J. Headache Pain. 2008. Vol. 9. P. 77-82.
  67. Wang S.J, Fuh J.L, Lu S.R. et.al. Quality of life differs among headache diagnoses: analysis of SF 36 survey in 901 headache patients // Pain. 2001. Vol. 89. P. 285-292.
  68. Weibelt S., Andress-Rothrock D., King W. et al. Suboccipital nerve blocks for suppression of chronic migraine: safety, efficacy, and predictors of outcome // Headache. 2010. Vol. 50. P. 1041-1044.

Statistics

Views

Abstract - 47

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2014 Ekusheva E.V., Damulin I.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies